The Reverie Labs Platform has been acquired by Ginkgo Bioworks

Today is a special day that begins a new chapter in Reverie's story, as Ginkgo Bioworks has acquired Reverie's platform and team!

For the last 6 years, our team at Reverie has been building state-of-the-art machine learning models to advance therapeutic discovery. We've built expertise in graph convolutional neural networks, large language models, and training methods for large-scale data. Most critically, we learned how to harness a tight data generation loop to advance multiple therapeutic programs from early screening through IND-enabling studies.

With this deal, Reverie is supercharging its ability to have an impact with machine learning models in the life sciences. Ginkgo operates a massive in-house life sciences Foundry, enabling it to generate massive quantities of data for training ML models. We're excited to see the possibilities ahead to build the next generation of models and make an impact in Ginkgo's extensive portfolio of biopharma and academic partners.

We want to thank everyone that supported us in this journey – first and foremost our incredible team, who made this company everything it is, and made coming to work an absolute joy for so many years. We also want to thank our investors, especially Y Combinator, Neo, First Round, Wireframe, and Ridgeback, who trusted us to build a new type of pharmaceutical company.

Reverie will continue to work to license its remaining small molecule programs. If interested, please get in touch at: contact@reverielabs.com.

The opportunities ahead are more exciting than ever. In Ginkgo, we've found a partner that can combine Reverie's technology and expertise with the data generation scale needed to get to the next level. We're so excited to see what comes next.

Thank you all for the incredible journey.

Jonah and Ankit